News Sentiment

CRNX sentiment intelligence

Crinetics Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 83.58 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+97.9% over one week, +142.5% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction 97.9% Price confirming higher
Trend fit Trend inactive 142.5% over four weeks
Fair value 109.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Stock Titan 7
simplywall.st 6
Investing.com 2
Motley Fool 2
Investing.com UK 2
MarketBeat 2
PR Newswire 2

Event Lens

What the news is about

Classified themes
Market update 23
Deals and strategy 21
Earnings 12
Analyst action 4
Regulatory and legal 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
Market source Direct company coverage

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share in an all-cash deal, valuing the acquisition at approximately $10 billion. The boards of both companies have unanimously approved the transaction, which is expected to close in Q3 of t

Tone
Positive 71/100
Event
Deals and strategy
Published
15 Jul 2026 21:01
Source
Market source
BioBuzz Direct company coverage

Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion

Fortress Biotech has acquired Crinetics Pharmaceuticals for approximately $10 billion, significantly enhancing its presence in the rare endocrine disease market. Crinetics' stock surged 99% on the news, despite facing profitability challenges and insider selling activity. The acq

Tone
Positive 64/100
Event
Market update
Published
15 Jul 2026 03:40
Source
BioBuzz
Investing.com Direct company coverage

Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD

Crinetics Pharmaceuticals Inc. (CRNX) stock has reached an all-time high of $83.77, reflecting a remarkable 163.21% increase over the past year. The company's market capitalization is now $8.83 billion, though InvestingPro analysis indicates it may be overvalued. This surge in st

Tone
Positive 63/100
Event
Market update
Published
14 Jul 2026 18:18
Source
Investing.com
Stock Traders Daily Direct company coverage

How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing

This article analyzes Crinetics Pharmaceuticals Inc. (CRNX) and its impact on rotational trading strategies, highlighting strong sentiment across all horizons. It provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-ti

Tone
Positive 73/100
Event
Market update
Published
11 Jul 2026 02:12
Source
Stock Traders Daily
Stock Titan Direct company coverage

Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal

Crinetics Pharmaceuticals has established one-year non-compete agreements with four key executives in connection with its upcoming merger with Vertex Pharmaceuticals. These agreements, effective post-merger, restrict the executives from working for competing businesses in Crineti

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 20:09
Source
Stock Titan
PR Newswire Direct company coverage

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)

Monteverde & Associates PC, a class action firm, has launched an investigation into Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) following its proposed acquisition by Vertex Pharmaceuticals Incorporated. The firm is examining whether the offered price of $85.00 per share in cas

Tone
Negative 38/100
Event
Deals and strategy
Published
10 Jul 2026 02:09
Source
PR Newswire
TradingView Direct company coverage

Price to book forward of Crinetics Pharmaceuticals Inc – DUS:6Z4

This article from TradingView provides financial information for Crinetics Pharmaceuticals Inc (DUS:6Z4), specifically focusing on its price-to-book forward ratio. The content is primarily a listing of navigation and data sourcing information, indicating that detailed financial m

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 01:40
Source
TradingView
Benzinga Direct company coverage

Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today

Crinetics Pharmaceuticals (NASDAQ: CRNX) has significantly outperformed the market over the last five years, with an average annual return of 33.07%. A $1000 investment in CRNX stock five years ago would now be worth $4,029.44, demonstrating the substantial impact of compounded r

Tone
Positive 94/100
Event
Market update
Published
09 Jul 2026 08:12
Source
Benzinga
Market source Direct company coverage

Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal

Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals, Viking Therapeutics (VKTX) has become a subject of renewed takeover speculation, particularly given its advancing obesity and metabolic disorder drug pipeline. The company's VK2735, in late-st

Tone
Positive 86/100
Event
Deals and strategy
Published
08 Jul 2026 05:12
Source
Market source
Market source Direct company coverage

Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit

JPMorgan raised its price target for Eli Lilly (LLY) due to strong demand for Mounjaro and Zepbound, expecting over $20 billion in sales for the quarter. Vertex Pharmaceuticals (VRTX) is acquiring Crinetics (CRNX) for approximately $10 billion, a move that will likely expand Vert

Tone
Positive 71/100
Event
Regulatory and legal
Published
07 Jul 2026 19:13
Source
Market source
TipRanks Direct company coverage

Vertex to Acquire Crinetics in $10 Billion Merger

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash, or $85 per share. This acquisition, expected to close in Q3 2026, will integrate Crinetics' PALSONIFY acromegaly franchise and atumelnant CAH program into Vertex's portfolio, aiming fo

Tone
Positive 75/100
Event
Deals and strategy
Published
07 Jul 2026 14:12
Source
TipRanks
BioSpace Direct company coverage

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Pharmaceuticals announced its intent to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, or $8.8 billion net of cash acquired, at $85.00 per share in cash. The acquisition will add Crinetics' recently launched PALSONIFY® for acromegaly and its Phase 3 can

Tone
Positive 85/100
Event
Deals and strategy
Published
07 Jul 2026 13:40
Source
BioSpace
Seeking Alpha Direct company coverage

Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know (NASDAQ:CRNX)

Vertex Pharmaceuticals announced its intention to acquire Crinetics Pharmaceuticals for approximately $10 billion, paying $85 per share. This acquisition aims to diversify Vertex's portfolio beyond cystic fibrosis, adding Crinetics' newly approved acromegaly therapy PALSONIFY and

Tone
Positive 71/100
Event
Deals and strategy
Published
07 Jul 2026 13:13
Source
Seeking Alpha
BioPharma Dive Direct company coverage

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex Pharmaceuticals announced its largest acquisition to date, planning to buy Crinetics Pharmaceuticals for $10 billion (or $85 per share) to expand into endocrine disorder treatments. This strategic move aims to diversify Vertex's portfolio beyond its successful cystic fibro

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 13:13
Source
BioPharma Dive
Pharmaceutical Technology Direct company coverage

Vertex signs agreement to acquire Crinetics for $10bn

Vertex Pharmaceuticals has signed a definitive agreement to acquire Crinetics Pharmaceuticals for nearly $10 billion. This acquisition, expected to close in Q3 2026, will add two main endocrinology assets to Vertex's portfolio: Palsonify for acromegaly and atumelnant for congenit

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 10:13
Source
Pharmaceutical Technology